Parstatin Prevents Renal Injury following Ischemia/Reperfusion and Radiocontrast Administration

American Journal of Nephrology

Volumn 36, Issue 3, 2012, Pages 278-286

  Diamantopoulos, Athanasios ^a   Kyriazis, Iason ^b   Geronatsiou, Katerina ^a   Papadaki, Helen ^a   Loudos, George ^e   Kagadis, George C ^c   Katsanos, Konstantinos ^a   Liatsikos, Evangelos ^d   Karnabatidis, Dimitrios ^a   Siamblis, Dimitrios ^a   Tsopanoglou, Nikos E ^b  

^a Department of Radiology ^*  (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c Medical Physics and   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Contrast induced nephropathy; Parstatin; Renal ischemia reperfusion injury

Indexed keywords

CREATININE; IOPROMIDE; PARSTATIN; PROTECTIVE AGENT; SODIUM ION; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXPERIMENTAL RABBIT; HISTOPATHOLOGY; KIDNEY ISCHEMIA; KIDNEY SCINTISCANNING; MALE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; SINGLE DRUG DOSE; SODIUM EXCRETION;

AMINO ACID SEQUENCE; ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; RABBITS; RADIONUCLIDE IMAGING; RATS; RATS, WISTAR; RECEPTOR, PAR-1; REPERFUSION INJURY; TIME FACTORS;

EID: 84865836869     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000341871     Document Type: Article

References (21)

1. Lameire N, Van Biesen W, Vanholder R: Acute renal failure. Lancet 2005; 365: 417-430.
2. Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936.
3. Liaro F, Pascual J: Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Failure Study Group. Kidney Int 1996; 50: 811-818.
4. Finn WF: The clinical and renal consequences of contrast-induced mephropathy. Nephrol Dial Transplant 2006; 21:i2-i10.
5. Chatterjee PK: Novel pharmacological approaches to the treatment of renal ischemiareperfusion injury: a comprehensive review. Naunyn-Schmiedeberg's Arch Pharmacol 2007; 376: 1-43.
6. Briguori C, Marenzi G: Contrast-induced nephropathy: pharmacological prophylaxis. Kidney Int Suppl 2006; 30-38.
7. Zania P, Gourni D, Aplin AC, Nicosia RF, Flordellis SC, Maragoudakis ME, Tsopanoglou NE: Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J Pharmacol Exp Ther 2009; 328: 378-389.
8. Strande JL, Widlansky ME, Tsopanoglou NE, Su J, Wang J, Hsu A, Routhu KV, Baker JE: Parstatin: a cryptic peptide involved in cardioprotection after ischemia and reperfusion injury. Cardiovasc Res 2009; 83: 325-334.
9. Pettersson G, Towart R, Grant D, Thyberg K, Golman K: The rabbit renal toxicity test: a sensitive in vivo test for the nephrotoxicity of contrast agents. Acad Radiol 2002; 9:S62-S64.
10. Chatterjee PK, Thiemermann C: An in vivo model of ischemia/reperfusion and inflammation of the kidneys of the rat. Methods Mol Biol 2003; 225: 223-237.
11. Morcos SK, Epstein FH, Haylor J, Dobrota M: Aspects of contrast media nephrotoxicity. Eur J Radiol 1996; 23: 178-184.
12. Tervahartiala P, Kivisaari, L, Kivisaari R, Vehmas T, Virtanen I: Structural changes in the renal proximal tubular cells induced by iodinated contrast media. Nephron 1997; 76: 96-102.
13. Chatterjee PK, Patel NSA, Kvale EO, Cuzzocrea S, Brown PAJ, Stewart KN, Mota-Filipe H, Thiemermann C: Inhibition of inducible nitric oxide synthase reduces renal ischemia reperfusion injury. Kidney Int 2002; 61: 862-871.
14. Xu T, Chen X, Wang XF, Huang XB, Qu XK, Ye HY, Zhang XD, Hou SK, Zhu JC: Electron paramagnetic resonance in monitoring of nitric oxide production after kidney transplantation in rats. Chin Med J 2004; 117: 1552-1557.
15. Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, Lee KW: Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. J Physiol Renal Physiol 2009; 297:F362-F370.
16. Detrenis S, Meschi M, Musini S, Savazzi G: Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20: 1542-1550.
17. Persson PB, Tepel M: Contrast mediuminduced nephropathy: the pathophysiology. Kidney Int Suppl 2006; 69:S8-S10.
18. Bonventre JV, Zuk A: Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485.
19. Lu CY, Hartono J, Senitko M, Chen J: The inflammatory response to ischemic acute kidney injury: a result of the 'right stuff' in the 'wrong place'? Curr Opin Nephrol Hypertens 2007; 16: 83-89.
20. Montoliu J: Clearance of inflammatory mediators through continuous renal replacement therapy. Blood Purif 1997; 15: 305-308.
21. Huang H, Vasilakis P, Zhong X, Shen J-K, Geronatsiou K, Papadaki H, Maragoudakis ME, Gartaganis SP, Vinores SA, Tsopanoglou NE: Parstatin suppresses ocular neovascularization and inflammation. Invest Ophthalmol Vis Sci 2010; 51: 5825-5832.